Association Between ALDH2 Gene Polymorphism and Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— AAAF  

Official title:

Association Between ALDH2 Gene Polymorphism and Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05524142
• Other study ID #: 2022-0404
• Status: Recruiting
• Start date: May 20, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: August 2022
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Yaping o Wang
• Phone: +8613805725837
• Email: yapingwang[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study is a case-control study. In this study, 2ml of vein blood samples were collected from patients with atrial fibrillation undergoing radiofrequency ablation and those in the control group who underwent electrophysiological examination alone and confirmed no arrhythmia. The purpose of this study is to identify the relationship between the aldehyde dehydrogenase 2 (ALDH2) gene polymorphism and susceptibility to atrial fibrillation, and to explore the relationship between the genotype of ALDH2 SNP and the prognosis of patients with atrial fibrillation undergoing radiofrequency ablation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Signed informed consent;

• Age 18-85 years old, gender is not limited; ? Case group: patients with clinical diagnosis of atrial fibrillation who underwent radiofrequency ablation; control group: patients with no arrhythmia confirmed by electrophysiological examination; ? Able to communicate well with investigators and comply with the entire trial requirements.

Exclusion Criteria:

• Those who cannot understand or refuse to sign the informed consent or follow-up; ?Pregnant women, mentally retarded, mental/cognitive insufficiency and other possible vulnerable groups

Related Conditions & MeSH terms

• Atrial Fibrillation

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	atrial fibrillation recurrence	atrial fibrillation recurrence	3 months